undamentalytics Newsletter
Sign in

Natera, Inc. revenue

Natera, Inc.'s revenue was $2.31bn in fiscal 2025, up 35.9% on the year before. Since fiscal 2013 ($55.2m) it has grown at a compound 36.5% a year. Over the last twelve months it was $2.71bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue551591902172112583023916258201,0831,6972,3062,707
Growth on the year before—+188.7%+19.5%+14.0%−2.8%+22.1%+17.3%+29.3%+60.0%+31.1%+32.0%+56.7%+35.9%—
Gross profit———8375100————————
Gross margin———38.0%35.8%38.6%————————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $2.3B 99.6% ▲ 36.2%
Licensing and Other $10.3M 0.4% ▼ 13.0%
Geography
Region Revenue Share YoY
United States $2.3B 98.2% ▲ 36.6%
Europe Middle East India and Africa $24.5M 1.1% ▲ 2.5%
Americas Excluding Us $9.4M 0.4% ▲ 41.3%
Other Geographic Areas $8M 0.3% ▼ 7.5%

From Natera, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Natera, Inc. $2.71bn 37.8% 42.7%
Exelixis, Inc. $2.50bn 9.1% 12.1%
United Therapeutics Corp $3.15bn 2.5% 14.3%
Biontech SE $3.24bn 9.0% —
Moderna $2.23bn -27.6% -40.6%
Biomarin Pharmaceutical Inc $3.41bn 11.2% 15.1%

Compare with peers

Head to head: EXEL vs NTRANTRA vs UTHRBNTX vs NTRAMRNA vs NTRA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Natera, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Natera, Inc.